- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Brainstorm Cell Therapeutics Inc (BCLI)
Brainstorm Cell Therapeutics Inc stock price live, this page displays OTC BCLI stock exchange data. View the BCLI premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Brainstorm Cell Therapeutics Inc real time stock price chart below.
What Is the Brainstorm Cell Therapeutics Inc Stock Price Today?
The Brainstorm Cell Therapeutics Inc stock price today is 0.730.
What Is the Stock Symbol for Brainstorm Cell Therapeutics Inc?
The stock symbol for Brainstorm Cell Therapeutics Inc is ""BCLI.""
What Stock Exchange Does Brainstorm Cell Therapeutics Inc Trade On?
Brainstorm Cell Therapeutics Inc is listed and trades on the OTC Markets stock exchange.
Is Brainstorm Cell Therapeutics Inc a Good Stock to Buy?
Determining whether Brainstorm Cell Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCLI quote. (ISIN: US10501E3009)
What Is the Brainstorm Cell Therapeutics Inc Stock Price Today?
The Brainstorm Cell Therapeutics Inc stock price today is 0.730.
What Is the Stock Symbol for Brainstorm Cell Therapeutics Inc?
The stock symbol for Brainstorm Cell Therapeutics Inc is ""BCLI.""
What Stock Exchange Does Brainstorm Cell Therapeutics Inc Trade On?
Brainstorm Cell Therapeutics Inc is listed and trades on the OTC Markets stock exchange.
Is Brainstorm Cell Therapeutics Inc a Good Stock to Buy?
Determining whether Brainstorm Cell Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCLI quote. (ISIN: US10501E3009)
OTC Markets
Currency in USD
0.730
+0.020(+2.82%)
Closed·
Fair Value
An estimate of a Brainstorm Cell Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.660
0.770
52 wk Range
0.521
4.964
BCLI Scorecard
Full Analysis
Significant return over the last week
BCLI is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Brainstorm Cell Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.6600.770
52 wk Range
0.5214.964
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BCLI Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Brainstorm Cell Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Neutral
Price Target
20.675
Upside
+2,732.19%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Brainstorm Cell Therapeutics Inc Company Profile
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company’s NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Brainstorm Cell Therapeutics Inc Earnings Call Summary for Q2/2025
- BrainStorm Cell Therapeutics focuses on NurOwn platform for ALS treatment, with sufficient capital for 2025 operations
- Stock price increased 3.79% to $0.656 post-earnings call, within 52-week range of $0.521 to $6
- Company emphasizes clinical trials and strategic partnerships to bolster market position in neurodegenerative treatments
- Detailed financial metrics not disclosed; future EPS forecasts indicate continued R&D focus with projected losses
- Risks include clinical trial outcomes, regulatory hurdles, and competition in the neurodegenerative disorder market
Last Updated: 14/08/2025, 14:12
Read Full TranscriptCompare BCLI to Peers and Sector
Metrics to compare | BCLI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCLIPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −3.1x | −0.6x | |
PEG Ratio | −0.01 | 0.03 | 0.00 | |
Price/Book | −1.3x | 2.5x | 2.6x | |
Price / LTM Sales | - | 136.8x | 3.3x | |
Upside (Analyst Target) | - | 137.2% | 38.7% | |
Fair Value Upside | Unlock | 6.0% | 5.1% | Unlock |
Analyst Ratings
0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 20.675
(+2,732.19% Upside)
Earnings
Latest Release
Aug 14, 2025
EPS / Forecast
-0.34 / -0.44
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Brainstorm Cell Therapeutics Trade On?
Brainstorm Cell Therapeutics is listed and trades on the OTC Markets stock exchange.
What Is the Stock Symbol for Brainstorm Cell Therapeutics?
The stock symbol for Brainstorm Cell Therapeutics is "BCLI."
What Is the Brainstorm Cell Therapeutics Market Cap?
As of today, Brainstorm Cell Therapeutics market cap is 8.28M.
What Is Brainstorm Cell Therapeutics's Earnings Per Share (TTM)?
The Brainstorm Cell Therapeutics EPS (TTM) is -1.76.
From a Technical Analysis Perspective, Is BCLI a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Brainstorm Cell Therapeutics Stock Split?
Brainstorm Cell Therapeutics has split 3 times.
How Many Employees Does Brainstorm Cell Therapeutics Have?
Brainstorm Cell Therapeutics has 29 employees.
What is the current trading status of Brainstorm Cell Therapeutics (BCLI)?
As of 28 Aug 2025, Brainstorm Cell Therapeutics (BCLI) is trading at a price of 0.730, with a previous close of 0.71. The stock has fluctuated within a day range of 0.660 to 0.770, while its 52-week range spans from 0.521 to 4.964.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.